Literature DB >> 18277615

Effect of ion-pair formation with bile salts on the in vitro cellular transport of berberine.

Hye-Won Chae1, In-Wha Kim, Hyo-Eon Jin, Dae-Duk Kim, Suk-Jae Chung, Chang-Koo Shim.   

Abstract

The objective of this study was to examine the effect of ion-pair complexation with endogenous bile salts on the transport of a quarternary ammonium organic cationic (OC) drug, berberine, across the Caco-2 and LLC-PK1 cell monolayers. The basolateral-to-apical (BL-AP) transport of berberine in Caco-2 cells was temperature dependent and 10-fold higher than that of the apical-to-basolateral (AP-BL) transport. Similar results were observed for the transport of berberine across the LLC-PK1 cells. Moreover, the BL-AP transport in the Caco-2 cells was significantly reduced by the cis-presence of P-glycoprotein (P-gp) inhibitors such as cyclosporine A, verapamil, and digoxin. These results suggest that an efflux transporter, probably P-gp, is involved in the Caco-2 cell transport. The Km and Vmax values for the carrier-mediated transport were estimated to be 83.4 mM and 7640 pmole/h/cm2, respectively. The apparent partition coefficient (APC) of berberine between n-octanol and a phosphate buffer (pH 7.4) was increased by the presence of an organic anion (OA), taurodeoxycholate (TDC, a bile salt), suggesting the formation of a lipophilic ion-pair complex between an OC (berberine) and an OA (TDC). Despite the ion-pair complexation, however, the BL-AP transport of berberine across the Caco-2 and LLC-PK1 cells was not altered by the cis-presence of bile salts or the rat bile juice. This is consistent with the reportedly unaltered secretory transport of a quarternary ammonium compound, tributylmethylammonium (TBuMA), across the Caco-2 cell monolayers in the cis-presence of bile salts or the rat bile juice, but not with our previous report in which the secretory transport of TBuMA across the LLC-PK1 cell was increased in the cis-presence of TDC. Therefore, the effect of ion-pair formation with the bile components or bile salts on the secretory transport of OCs appears to depend on the molecular properties of OCs (e.g., molecular weight, lipophilicity and affinity to relevant transporters) and the characteristics of cell strains (e.g., expression and contribution of responsible transporters to the transport).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18277615     DOI: 10.1007/s12272-008-1127-4

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  7 in total

1.  Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins.

Authors:  Francesco Di Pierro; Iaele Bellone; Giuliana Rapacioli; Pietro Putignano
Journal:  Diabetes Metab Syndr Obes       Date:  2015-02-04       Impact factor: 3.168

2.  Tissue distribution of berberine and its metabolites after oral administration in rats.

Authors:  Xiang-Shan Tan; Jing-Yi Ma; Ru Feng; Chao Ma; Wen-Jing Chen; Yu-Peng Sun; Jie Fu; Min Huang; Chi-Yu He; Jia-Wen Shou; Wen-Yi He; Yan Wang; Jian-Dong Jiang
Journal:  PLoS One       Date:  2013-10-31       Impact factor: 3.240

3.  Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in patients with dyslipidemia.

Authors:  Francesco Di Pierro; Pietro Putignano; Tarcisio Ferrara; Carmela Raiola; Giuliana Rapacioli; Nicola Villanova
Journal:  Clin Pharmacol       Date:  2016-12-21

4.  Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control.

Authors:  Francesco Di Pierro; Nicola Villanova; Federica Agostini; Rebecca Marzocchi; Valentina Soverini; Giulio Marchesini
Journal:  Diabetes Metab Syndr Obes       Date:  2012-07-17       Impact factor: 3.168

Review 5.  Roles of chemical complexity and evolutionary theory in some hepatic and intestinal enzymatic systems in chemical reproducibility and clinical efficiency of herbal derivatives.

Authors:  Francesco Di Pierro
Journal:  ScientificWorldJournal       Date:  2014-04-06

6.  Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes.

Authors:  Francesco Di Pierro; Pietro Putignano; Nicola Villanova; Luca Montesi; Simona Moscatiello; Giulio Marchesini
Journal:  Clin Pharmacol       Date:  2013-11-19

7.  Gut Microbiota-Regulated Pharmacokinetics of Berberine and Active Metabolites in Beagle Dogs After Oral Administration.

Authors:  Ru Feng; Zhen-Xiong Zhao; Shu-Rong Ma; Fang Guo; Yan Wang; Jian-Dong Jiang
Journal:  Front Pharmacol       Date:  2018-03-21       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.